Granulocyte colony-stimulating factor-primed bone marrow: an excellent stem-cell source for transplantation in acute myelocytic leukemia and chronic myelocytic leukemia.
- Author:
Yuhang LI
;
Min JIANG
;
Chen XU
;
Jianlin CHEN
;
Botao LI
;
Jun WANG
;
Jiangwei HU
;
Hongmei NING
;
Hu CHEN
;
Shuiping CHEN
;
Liangding HU
1
Author Information
- Publication Type:Journal Article
- MeSH: Adolescent; Adult; Aged; Bone Marrow; drug effects; Bone Marrow Transplantation; methods; Child; Female; Granulocyte Colony-Stimulating Factor; pharmacology; Humans; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; therapy; Leukemia, Myeloid, Acute; therapy; Male; Middle Aged; Retrospective Studies; Stem Cells; cytology; Young Adult
- From: Chinese Medical Journal 2015;128(1):20-24
- CountryChina
- Language:English
-
Abstract:
BACKGROUNDSteady-state bone marrow (SS-BM) and granulocyte colony-stimulating growth factor-primed BM/peripheral blood stem-cell (G-BM/G-PBSC) are the main stem-cell sources used in allogeneic hematopoietic stem-cell transplantation. Here, we evaluated the treatment effects of SS-BM and G-BM/G-PBSC in human leucocyte antigen (HLA)-identical sibling transplantation.
METHODSA total of 226 patients (acute myelogenous leukemia-complete remission 1, chronic myelogenous leukemia-chronic phase 1) received SS-BM, G-BM, or G-PBSC from an HLA-identical sibling. Clinical outcomes (graft-versus-host disease [GVHD], overall survival, transplant-related mortality [TRM], and leukemia-free survival [LFS]) were analyzed.
RESULTSWhen compared to SS-BM, G-BM gave faster recovery time to neutrophil or platelet (P < 0.05). Incidence of grade III-IV acute GVHD and extensive chronic GVHD (cGVHD) was lower than seen with SS-BM (P < 0.05) and similar to G-PBSC. Although the incidence of cGVHD in the G-BM group was similar to SS-BM, both were lower than G-PBSC (P < 0.05). G-BM and G-PBSC exhibited similar survival, LFS, and TRM, but were significantly different from SS-BM (P < 0.05). There were no significant differences in leukemia relapse rates among the groups (P > 0.05).
CONCLUSIONSG-CSF-primed bone marrow shared the advantages of G-PBSC and SS-BM. We conclude that G-BM is an excellent stem-cell source that may be preferable to G-PBSC or SS-BM in patients receiving HLA-identical sibling hematopoietic stem-cell transplantation.
